Literature DB >> 2300517

Oral ciprofloxacin for osteomyelitis.

R R MacGregor1, A L Graziani, J L Esterhai.   

Abstract

Ciprofloxacin is a new, oral, broad spectrum fluoroquinolone antibiotic which has a long serum half-life, a low incidence of significant adverse reactions, and is administered twice daily. Eighteen patients with osteomyelitis were treated with ciprofloxacin, 750 mg orally twice daily. The mean age of the patients was 43 years (range, 21 to 73 years); 12 were men. The duration of treatment ranged from 5 to 52 weeks (mean, 20.0 +/- 15.7 weeks). At follow up (mean, 18 +/- 8.5 months; range, 4 to 34.5 months), 11 patients (61.6%) achieved arrest of infection, 4 (22.2%) had improved with therapy, and 3 (16.6%) failed to improve. Ciprofloxacin was well tolerated. Four case histories are given.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300517     DOI: 10.3928/0147-7447-19900101-10

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  3 in total

Review 1.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 2.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.